一个药物评估叙事审查的克拉迪宾作为治疗多发性硬化症
Sarah-Jane Martin1,2, Shane Arsenault2, Jiwon Oh2
1School of Infection and Immunity, University of Glasgow, Glasgow, UK.
Neurodegenerative disease management
|July 21, 2025
概括
克拉德里宾片为多发性硬化症提供了一种独特的口服免疫复合疗法. 这种方法通过选择性向淋巴细胞提供持久的好处,可能在没有慢性治疗的情况下降低疾病活性.
科学领域:
- 免疫学 免疫学 免疫学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 是一种免疫媒介的中枢神经系统疾病.
- 许多疾病修饰疗法 (DMT) 可用于MS治疗.
- 免疫复制疗法 (IRT) 提供了潜在的持续性MS治疗益处,而无需慢性管理.
研究的目的:
- 审查克拉德里宾片作为多发性硬化症口服IRT的疗效和安全数据.
- 总结临床试验和现实世界的证据,用于复发性多发性硬化症中的克拉迪宾片.
主要方法:
- 发表的临床试验和现实研究的叙述性综述.
- 对克拉德里宾片的疗效和安全性数据的分析.
主要成果:
- 克拉迪宾片选择性地向淋巴细胞,诱导短暂的淋巴缺血,随后免疫复原.
- 这种机制可能会在多发性硬化症中带来持久的治疗效益.
- 在减少短期和长期疾病活性的有效性已被证明.
结论:
- 克拉迪片是一种高效的口服IRT,具有间歇性剂量表.
- 它的疗效和安全性使其成为许多复发性多发性硬化症患者的有吸引力的治疗选择.
- 在不需要慢性服用的情况下获得持久益处的潜力是关键优势.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
Myasthenia Gravis: Overview and Treatment
2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


